A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: * Administration of combination HIV-specific broadly neutralizing antibody (bNAb) therapy in addition to ART during acute HIV infection (AHI) will be safe. * Participants who receive combination bNAb therapy in addition to ART during AHI will be more likely to demonstrate a delay in time to HIV-1 RNA ≥1,000 copies/mL for 4 consecutive weeks during an Analytical Treatment Interruption (ATI) compared to participants who receive placebo plus ART. * Participants who receive combination bNAb therapy in addition to ART during AHI will demonstrate lower viral reservoirs and enhanced HIV-specific immunity compared to participants who receive placebo plus ART.

* Between 18 and 70 years of age * Body weight under 115 kg (approximately 253 pounds) * Evidence of recently acquiring HIV * Not pregnant or breastfeeding * No recent use of medications to prevent or treat HIV * Able and willing to provide informed consent to study and its procedures which include * initiating HIV medications (also called antiretroviral treatment or ART) following enrollment, * A later, monitored pause in HIV medications (also called an analytical treatment interruption, or ATI) * While pausing HIV treatment per study guidelines until resuppressed following treatment restart, agree to using barrier contraception to prevent HIV acquisition in sexual partners * Agree to use effective contraception to prevent pregnancy in oneself and sexual partners who may become pregnant.